Sanofi Ends Itepekimab and Balinatunfib Programs

Company Sanofi Event Type Pipeline Discontinuation (Portfolio Prioritization) Modality Anti-IL-33 monoclonal antibody (itepekimab); oral TNF inhibitor (balinatunfib) Asset Itepekimab (partnered with Regeneron) and balinatunfib Target IL-33 (itepekimab); TNF (balinatunfib) Disease Area COPD and chronic rhinosinusitis (itepekimab); Crohn’s disease and ulcerative colitis (balinatunfib) Summary Sanofi discontinued…